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Abstract. The aim of our 10-year study was to test the effectiveness of topical therapy
based on 0.18% isotretinoin, comparing itwith thatmost frequently used, i.e. at 0.05%
concentration. Seventy patients with an established diagnosis of oral lichen planus
were involved in the study. The patients were randomly divided into two groups, and
the drug was administered topically at 0.05% and 0.18% concentrations.
The drug at the higher concentration, according to the same protocol, was
administered to the patients who did not benefit from the therapy at the lower
concentration. None of the cases of reticular lichen planus showed clinical or
histological improvement. In contrast, the atrophic–erosive forms showed a
significant improvement, both clinical and histological: in 26 patients (at 0.18%
concentration) and in nine patients (at 0.05% concentration), the symptoms, as well
as the erosions or ulcers observed, disappeared. The disappearance of dysplasic
phenomena was observed at 0.18% concentration. Topical application of the drug
was accompanied by an increase in soreness and pain, as well as greater sensitivity
to hot foods. However, these side effects were transitory, and considered acceptable
by the patients. The proposed therapeutic protocol was effective towards highly
active atrophic–erosive oral lichen planus with dysplasic phenomena, which is the
form of the disease at higher risk of malignant evolution.0901-5027/010067 + 05 $30.00/0 # 2005 International Association of Oral and Maxillofacial SurgeoClinical Paper
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Accepted for publication 3 May 2005An accurate literature review has shown
that Vitamin A and its derivatives have
very important biological functions2,3,5. In
vitro Vitamin A inhibits the malignant
transformation caused by chemical carci-nogenetic agents, ionizing radiations and
viruses by interfering with the first phase
of epithelial transformation, and such a
preventive effect has proven useful even
for oral mucosa cells14,15.In the pre-malignant state, the oral
mucosa progresses through various grades
of epithelial dysplasia, with the potential
to convert to squamous cell carcinoma.
Both topical and systemic retinoids werens. Published by Elsevier Ltd. All rights reserved.
68 Scardina et al.found to suppress head and neck and lung
carcinogenesis in animal models, and inhi-
bit carcinogenesis in individuals with pre-
malignant lesions and a high risk of devel-
oping cancer of the aerodigestive tract7,8.
Following those studies, which have
shown the important biological effects
of Vitamin A and its derivatives, our study
was aimed at evaluating the therapeutic
effects of isotretinoin at different concen-
trations (0.05% and 0.18%) in themanage-
ment of oral lichen planus (OLP)9,24.
Often no medication is necessary for the
benign form of this disease (reticular
lichen planus). In the case of severe pain
and a burning sensation, high-potency
topical corticosteroids remain the most
reliably effective treatment. Other avail-
able treatments are topical cyclosporine,
tacrolimus, retinoids and other immuno-
suppressive agents. Systemic corticoster-
oids may be indicated in patients whose
condition is unresponsive to topical corti-
costeroids. OLP remains a challenging
disease to treat, in spite of the numerous
treatments tried. Several studies have been
carried out aimed at evaluating the effect
of Vitamin A derivatives on OLP1,4,6, but
our study is characterized by histological
monitoring before and after the treatment,
by 10-year and 5-year follow-up of 19 and
20 cases, respectively, by evaluation of the
timing of relapse, by application of dif-
ferent concentrations (0.05% and 0.18%)
of isotretinoin, and by the method of
administration of the therapy.Materials and methods
Seventy patients (M/F: 30/40; mean age:
57.78  8.9; range: 39–73), who from
1994 to 2004 came to our department
for diagnostic investigations with a diag-
nosis of suspected OLP, were examined.
Patients were always followed by the same
operator. After accurate anamnesis and
clinical examination, and having con-
firmed the diagnosis of suspected OLP,
a histological sample was taken for final
confirmation of the diagnosis. The biopsy
was carried out under local anaesthesia
with the punch technique in all the patients
examined13.
After histological confirmation of the
diagnosis, the patients were included in
the study if they gave their written consent
after being properly informed about the
therapeutic aspects of the experimental
protocol. Patients with major disease (sys-
temic manifestations) or those with histo-
logical diagnosis of carcinoma in situwere
excluded from the study. Of the 70
patients involved, 37 were smokers and
none were spirit drinkers. All the patientswere informed about the importance of
avoiding risk factors, such as smoking
and alcohol, in order to reduce the possi-
bility of lesion evolution and to make the
treatment effective.
The patients were divided into two
groups: to the 35 patients of group A
was administered a galenic preparation
based on 0.18% isotretinoin; to the 35
patients of group B isotretinoin was also
administered, but at a lower concentration,
i.e. 0.05%. The patients were randomly
assigned to each group, since they were
selected in order of access to our depart-
ment. The drug was administered topically
twice a day for three consecutive months;
then it was suspended for 1 month, and the
biopsy was repeated for histological fol-
low up. The treatment used was not known
to the patient or clinician. All the patients
were advised to apply the drug to a gauze
and then apply this to the lesion site. The
use of gauze permits application for an
adequate time period, reducing salivary
interference. The patients were advised
to keep the gauze in place for at least
10 consecutive minutes. The application
was carried out twice a day, in the morning
after breakfast and in the evening after
dinner, and after accurate oral care. After
three consecutive months of therapy, and
after clinical and histological observa-
tions, the patients to whom the drug at
lower concentration had been adminis-
tered who did not show a clinical and
histological improvement in the disease
were treated with the drug at the higher
concentration according to the same ther-
apeutic protocol, and then evaluated again
both at a clinical and a histological level.
Before starting therapy, all lesions were
given a clinical score classifying the
severity of OLP. The score ranged from
0 to 3 as follows: 3 = white striae with
erosive area; 2 = white striae with atrophic
area; 1 = white striae with no erythema-
tous area; 0 = normal mucous. The visual
analogue scale was used for the scoring of
pain, with scores from 0 (no pain) to 10
(extreme pain). The Wilcoxon rank sum
test was used for the analysis of the sign
scores.
The galenical preparation was made in
our laboratories, in a dark room, and
stored in containers protected from the
light by tinfoil. The drug was prepared
at two different concentrations: 0.05%
concentration, used in many published
studies12,20 and a higher concentration
of 0.18%, chosen from our experience.
The isotretinoin, taken from capsules mar-
keted in Italy with the name of Roaccutan
Roche, was included in 50 g of carboxy-
methylcellulose-based gel (marketed inItaly with the name of Oralbalance gel).
After taking the isotretinoin from the cap-
sules by means of 5 cc syringes, the active
principle was included in the gel; subse-
quently, the preparation was homoge-
nized. Then, the patients were advised
to store the galenic preparation in the
refrigerator.
During the first 3 months of treatment,
the patients were observed every 15 days,
to evaluate the clinical progress of the
lesion and, above all, to check the method
of application of the drug, which was
prepared again before it was finished, as
well as to evaluate any appearance of
undesired effects. Subsequently, the treat-
ment was interrupted for 1 month, and
each patient was evaluated both from
the clinical and the histological point of
view, to monitor any lesion modifications.
The patients continued to be followed to
evaluate the preservation of the results
obtained and any lesion relapse following
therapy interruption. A group of 19
patients, in particular, had a 10-year fol-
low up, while a group of 20 had a 5-year
follow up. The drug (isotretinoin) was
administered topically twice a day for
three consecutive months; then it was
suspended. These patients were examined
every 12 months to evaluate the clinical
and histological aspect of the lesions.Results
The 70 patients with OLP showed differ-
ent clinical and histological aspects. Ten
cases had the characteristics of reticular
lichen planus, 19 the aspect of white striae
with an atrophic area, and 41 the aspect of
white striae with an erosive area. Of the
atrophic–erosive cases, nine showed dys-
plasia in progress or very high activity of
the disease. In all the patients, the signs of
the disease were located in correspon-
dence with the right and left buccal
mucosa, and also with the lingual back
in 44 cases.
Prior to therapy, the average score of
clinical severity was 2.4 and 2.5 in group
A and group B, respectively. There was no
statistically significant difference in clin-
ical severity between the two groups
(P > 0.01).
Symptoms were absent in patients with
the reticular form (pain score = 0),
whereas patients with the atrophic–erosive
form reported soreness and pain, particu-
larly while eating acidic and hot foods
(average pain score = 8). In 13 cases,
the patients reported difficulty in speaking
(average pain score = 10). The patients
with lingual localization also reported
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ig. 1. Clinical aspect before therapy (isotretinoin 0.18%).Ftaste alteration and considerable difficulty
in eating.
Following application of the galenic
preparation, modification of the clinical/
histological pictures differed both accord-
ing to drug concentration and the clinical
characteristics of the disease. In all the
cases observed, topical application of the
drug caused, during the first 30 min, an
increase in soreness and pain, as well as a
greater sensitivity to hot foods. However,
these side effects were transitory, and
considered acceptable by the patients.
No other undesired effects of the drug at
either concentration were reported by the
patients.
In the group of patients subjected to the
drug at higher concentration, six had reti-
cular lichen planus, while nine showed the
atrophic form and twenty the erosive clin-
ical aspect. After three consecutive months
of treatment, the patients with reticular
lichen planus did not show any modifica-
tion in the clinical aspect of the lesion; in
contrast, in 26 (74.3%) patients with the
atrophic–erosive form, the symptoms, as
well as the erosions or ulcers observed,
disappeared. At a histological level, the
picture was stationary in the reticular form;
in contrast, in the atrophic–erosive form
epithelio-lesive activity decreased and in
three of these cases the dysplasia disap-
peared (Table 1).
In the second group of patients who
received the drug at lower concentration,
4 had reticular lichen planus, while 10
showed the atrophic form and 21 the
erosive clinical aspect. After three conse-
cutive months of treatment, the patients
with reticular lichen planus did not show
any modification in the clinical aspect of
the lesion; in contrast, in nine patients
(25.7%) with the atrophic–erosive form,
the symptoms, as well as the erosions or
ulcers observed, disappeared. At a histo-
logical level, the picture was stationary inthe reticular form; in contrast, in nine
cases with the atrophic–erosive form
epithelio-lesive activity decreased, but in
six of these cases dysplasia remained;
therefore, in 22 cases (62.8%) with a
diagnosis of atrophic–erosive lichen pla-
nus, neither a clinical nor a histological
improvement of the disease was observed
(Table 1). The change noted in the patients
receiving the drug at higher concentration
was statistically significantly greater than
that in the patients receiving the drug at
lower concentration (P < 0.01).
The 22 cases with no clinical/histologi-
cal modification were then administered
the drug at the higher concentration: clin-
ical and histological improvement was
observed in 20 patients (91%) (Figs. 1
and 2; Table 1). Even the six patients with
dysplasia at the post-therapy histological
control showed improvement, with the
disappearance of dysplasic phenomena.
Prior to therapy the average pain score
was 7.7 and 7.8 in group A and group B
patients, respectively (P > 0.01). At the
end of therapy the average pain score was
0 and 4.2 in group A and group B, respec-
tively (P > 0.01).
Of the 70 patients observed and fol-
lowed during the 10 years of study, the
original group was composed of 19
patients (6 with the reticular form, 5 with
the atrophic form and 8 with the erosive
form). The 10-year and 5-year follow-up
patients are still under observation and
show a completely asymptomatic picture;
a relapse of the lesion occurred in only two
cases, and was treated with the same ther-
apeutic protocol (Table 1). None of the 70
cases involved in the study showed malig-
nant evolution of the lesion.Discussion
Several prospective and retrospective stu-
dies have reported OLP as having an
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ig. 2. Clinical aspect after therapy (isotretinoin 0.18%).Fincreased potential for malignant develop-
ment; the reported transformation rates
vary from 0% to 9%10,18,19,23. This is a
matter of serious controversy: KRUTCHKOFF
& EISENBERG stated that some of the
reported OLP cases developing oral can-
cer were in fact not OLP, but rather dys-
plastic lesions with lichenoid features16.
The implication of this observation is that
patients with dysplasia represent a risk
group, which can be identified by the
appropriate use of available diagnostic
methods and, as such, can be distinguished
from patients with OLP with no dysplasia-
related increased risk of development of
oral cancer. The treatment of OLP remains
a real challenge for clinicians who deal
with this patient population and thus with
diagnosis of this disease. The most effec-
tive treatment method to control the signs
and symptoms of the disease is a short
courses of systemic steroids and topical
high-potency corticosteroids11,25. Other
forms of therapy include the use of cyclos-
porine and retinoids, both systemic and
topical12,17,20,21,22.
Experimental studies of the therapeutic
effectiveness of Vitamin A and its deri-
vatives have shown continuous evolution.
There have, over the years, been three
main objectives: synthesis of new vitamin
derivatives that result in lower accumula-
tion in adipose tissue and lower organism
permanence, and therefore also a reduc-
tion in undesired effects; finding the mini-
mum effective dose; determining the most
efficient method of administration14,15.
Over the years, different opinions have
been expressed regarding the effective-
ness of OLP treatment by means of Vita-
min A synthetic derivatives. Our study
highlights two extremely important, inno-
vative aspects of the treatment: the method
of application of the drug and the concen-
tration used. Regarding the first aspect,
since the oral cavity is a wet environment,it is not easy to apply a drug and, above all,
for it to remain on the lesions for a given
time. The use of gauze reduces the cleans-
ing effect of saliva, and also makes drug
application fairly simple as reported by all
the patients. As for the second aspect,
none of the published studies used the
same drug concentration as the present
study (0.18% isotretinoin). We believe
that our concentration is the most effective
and acceptable to patients; a higher con-
centration could have undesired effects,
such as soreness, which would make com-
pletion of the therapy cycle by the patients
extremely difficult. We only observed a
transitory soreness, which disappeared in
the first 30 min after application. In our
opinion, therefore, the frequently contrast-
ing results on the effectiveness of Vitamin
A synthetic derivatives in OLP therapy are
mainly related to these two aspects.
The effectiveness of the therapeutic
protocol varies according to the clinical
and histological aspect of the lesion, the
treatment being less effective when
applied to the reticular form of the disease.
The probability of malignant evolution of
OLP is closely linked to its clinical and
histological aspect. Since the reticular
form is less prone to evolve into oral
carcinoma, this variation in effectiveness
does not limit the applicability of Vitamin
A derivatives in OLP treatment. On the
contrary, the study shows that our thera-
peutic protocol reduces the epithelio-
lesive activity of the disease. As regards
dysplasia, the disappearance of this aspect
was seen in all of the nine cases observed
in the study. An important finding of our
study is thus that the therapeutic protocol
proves more effective against the forms of
OLP at higher risk of malignant evolution
at a histological level. From the clinical
point of view also, a considerable effec-
tiveness was observed in the resolution of
erosive–ulcerous forms.Of the 70 patients involved, 37 were
smokers, and none were spirit drinkers.
Another aspect worth mentioning is that
of disease relapse. Our long clinical
experience allows us to maintain that
relapse is connected not so much to the
therapy as to the intrinsic characteristics
of the disease itself. Over the years, sev-
eral patients showed a worsening of
symptoms, accompanied by a worsening
of the disease at both a clinical and a
histological level. These ‘relapses’, how-
ever, were always controlled using the
same therapeutic approach.
The administration method of our ther-
apeutic approach is topical. This is impor-
tant because the undesired effects of the
therapy are reduced and made exclusively
local and are, in any case, limited in time.
Topical administration virtually elimi-
nates the risk of teratogenesis, common
to every therapy with Vitamin A deriva-
tives. Also, it is known that systemic
administration should be avoided in fertile
women, and must be followed by contra-
ceptive therapy for at least 2 years, since
retinoids are deposited at the level of
adipose tissue and slowly released. Topi-
cal administration makes our therapeutic
protocol applicable in all those cases in
which systemic corticosteroid treatment is
contraindicated. Of our patients, five were
hypertensive and nine diabetic; for these,
corticosteroid therapy was not recom-
mended. Topical corticosteroid applica-
tion is often associated with fungus
superinfection, which can make OLP
management more difficult. The adminis-
tration of clorexidine can control this pro-
blem, which was completely absent,
however, with our approach. Given its
effectiveness, our therapeutic approach
can be considered valid not only for the
cases in which classic systemic corticos-
teroid treatment is contraindicated, but for
all cases of atrophic–erosive OLP.
In conclusion, the present study has
demonstrated that isotretinoin, whether
at 0.05% or 0.18% concentration, is an
effective method of controlling the symp-
toms and signs of OLP when applied
topically. Although the sample size is
small, it would also appear that topical
isotretinoin may reverse any dysplastic
change associated with the disease. There
is now a need to undertake a much more
detailed randomized control trial to con-
firm these observations.References
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